RAC1 and hepatocellular carcinoma: We demonstrated that MG53 inhibited HCC progression and enhanced chemosensitivity through directly targeting RAC1 for ubiquitination modification at Lys5 residue, which further led to the suppression of RAC1 activity and inhibition of the downstream MAPK pathway.